CoChat

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Open access
Marseille, Elliot, Kahn, James G., Yazar-Klosinski, Berra, Doblin, Rick · 2020 · PLOS ONE
Cited by 56

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phase 2 trials. Its cost-effectiveness is unknown. METHODS AND FINDINGS: To assess the cost-effectiveness of MDMA-assisted psychotherapy (MAP) from the health care payer's perspective, we constructed a decision-analytic Markov model to portray the costs and health benefits of treating patients with chronic, severe, or extreme, treatment-resistant PTSD with MAP. In six double-blind phase 2 trials, MAP consisted of a mean of 2.5 90-minute trauma-focused psychotherapy sessions before two 8-hour sessions with MDMA (mean dose of 125 mg), followed by a mean of 3.5 integration sessions for each active session. The control group received an inactive placebo or 25-40 mg. of MDMA, and otherwise followed the same regimen. Our model calculates net medical costs, mortality, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Efficacy was based on the pooled results of six randomized controlled phase 2 trials with 105 subjects; and a four-year follow-up of 19 subjects. Other inputs were based on published literature and on assumptions when data were unavailable. We modeled results over a 30-year analytic horizon and conducted extensive sensitivity analyses. Our model calculates expected medical costs, mortality, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio. Future costs and QALYs were discounted at 3% per year. For 1,000 individuals, MAP generates discounted net savings of $103.2 million over 30 years while accruing 5,553 discounted QALYs, compared to continued standard of care. MAP breaks even on cost at 3.1 years while delivering 918 QALYs. Making the conservative assumption that benefits cease after one year, MAP would accrue net costs of $7.6 million while generating 288 QALYS, or $26,427 per QALY gained. CONCLUSION: MAP provided to patients with severe or extreme, chronic PTSD appears to be cost-saving while delivering substantial clinical benefit. Third-party payers are likely to save money within three years by covering this form of therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0239997

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 11 references

Research works printed but not linked: 23

  1. MG Haviland, 2016, Posttraumatic Stress Disorder-Related Hospitalizations in the United States (2002–2011): Rates, Co-Occurring Illnesses, Suicidal Ideation/Self-Harm, and Hospital Charges, The Journal of nervous and mental disease, 204, 78, 10.1097/NMD.0000000000000432 · DOI
  2. J Sareen, 2007, Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample, Psychosom Med, 69, 242, 10.1097/PSY.0b013e31803146d8 · DOI · Paper page
  3. MT Davis, 2014, Posttraumatic stress disorder and suicidal ideation: The role of specific symptoms within the framework of the interpersonal-psychological theory of suicide, Psychological Trauma: Theory, Research, Practice, and Policy, 6, 610, 10.1037/a0033941 · DOI
  4. H Ramsawh, 2014, Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army, Journal of affective disorders, 161, 116, 10.1016/j.jad.2014.03.016 · DOI · Paper page
  5. ML Pacella, 2013, The physical health consequences of PTSD and PTSD symptoms: a meta-analytic review, J Anxiety Disord, 27, 33, 10.1016/j.janxdis.2012.08.004 · DOI · Paper page
  6. N Ahmadi, 2011, Post-traumatic stress disorder, coronary atherosclerosis, and mortality, The American journal of cardiology, 108, 29, 10.1016/j.amjcard.2011.02.340 · DOI · Paper page
  7. RC Kessler, 2005, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication, Arch Gen Psychiatry, 62, 593, 10.1001/archpsyc.62.6.593 · DOI · Paper page
  8. RC Kessler, 2005, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication, Arch Gen Psychiatry, 62, 617, 10.1001/archpsyc.62.6.617 · DOI · Paper page
  9. C Steinert, 2015, The course of PTSD in naturalistic long-term studies: high variability of outcomes. A systematic review, Nord J Psychiatry, 69, 483, 10.3109/08039488.2015.1005023 · DOI · Paper page
  10. K Brady, 2000, Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress DisorderA Randomized Controlled Trial. JAMA: the journal of the, American Medical Association, 283, 1837, 10.1001/jama.283.14.1837 · DOI · Paper page
  11. P Oehen, 2012, A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD), Journal of psychopharmacology, 27, 40, 10.1177/0269881112464827 · DOI · Paper page
  12. FW Weathers, 2001, Clinician-administered PTSD scale: a review of the first ten years of research, Depression and anxiety, 13, 132, 10.1002/da.1029 · DOI · Paper page
  13. MC Mithoefer, 2013, Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study, Journal of psychopharmacology, 27, 28, 10.1177/0269881112456611 · DOI · Paper page
  14. Z Solomon, 2006, Trajectories of PTSD: a 20-year longitudinal study, Am J Psychiatry, 163, 659, 10.1176/ajp.2006.163.4.659 · DOI · Paper page
  15. N Morina, 2014, Remission from post-traumatic stress disorder in adults: a systematic review and meta-analysis of long term outcome studies, Clin Psychol Rev, 34, 249, 10.1016/j.cpr.2014.03.002 · DOI · Paper page
  16. MJ Mancino, 2006, Quality-adjusted health status in veterans with posttraumatic stress disorder, The Journal of nervous and mental disease, 194, 877, 10.1097/01.nmd.0000244686.79689.21 · DOI
  17. JI Ivanova, 2011, Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance, The American journal of managed care, 17, e314
  18. TA Lavelle, 2018, Cost-effectiveness of collaborative care for depression and PTSD in military personnel, The American journal of managed care, 24, 91
  19. D Chan, 2009, Health care utilization and its costs for depressed veterans with and without comorbid PTSD symptoms, Psychiatric services, 60, 1612, 10.1176/ps.2009.60.12.1612 · DOI · Paper page
  20. EA Walker, 2003, Health care costs associated with posttraumatic stress disorder symptoms in women, Arch Gen Psychiatry, 60, 369, 10.1001/archpsyc.60.4.369 · DOI · Paper page
  21. P Fronstin, 2017, Health Plan Switching: A Case Study—Implications for Private- and Public-Health-Insurance Exchanges and Increased Health Plan Choice, EBRI Issue Brief, 1
  22. AL Goldman, 2020, Among Low-Income Adults Enrolled In Medicaid, Churning Decreased After The Affordable Care Act, Health affairs, 39, 85, 10.1377/hlthaff.2019.00378 · DOI
  23. E Savoca, 2000, The civilian labor market experiences of Vietnam-era veterans: the influence of psychiatric disorders, The journal of mental health policy and economics, 3, 199, 10.1002/mhp.102 · DOI · Paper page

Cited by

See all 56

Metadata

Authors
Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R.
Venue
PLOS ONE
Published
2020-10-14
Volume
15
Issue
10
Pages
e0239997
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3093269897
Cited by
56
References
11
FWCI
6.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. https://app.cochat.ai/papers/10.1371/journal.pone.0239997
The paper
Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020). The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLOS ONE. https://doi.org/10.1371/journal.pone.0239997

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.